Weston Park Hospital

Sheffield S10 2Sj

6 studies enrolling now · 32 studies all time

What they study most

Brain and Central Nervous System Tumors, Breast Cancer, Breast Cancer With Low to Intermediate HER2 Expression, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Clear Cell Renal Carcinoma, Extensive-stage Small Cell Lung Cancer, Gastro-enteropancreatic Neuroendocrine Tumor, Gastrointestinal Stromal Tumors, Glioblastoma, Lymphoma, Non-Hodgkin, Malignant Pleural Mesothelioma

Studies at this site

• A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer — Recruiting now
• Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation — Recruiting now
• EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma — Recruiting now
• A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer — Recruiting now
• A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract — Recruiting now
• Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) — Recruiting now
• A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours — Recruiting now
• A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression — Stopped early
• A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) — Completed
• A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy — Running, not enrolling
• A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib — Running, not enrolling
• Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET — Running, not enrolling
• A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer — Completed
• A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors — Completed
• A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE) — Completed
• Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH) — Running, not enrolling
• A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy — Stopped early
• Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma — Completed
• Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse — Stopped early
• DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer — Completed
• A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130) — Completed
• Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma — Completed
• Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer — Completed
• TroVax Renal Immunotherapy Survival Trial — Completed
• BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL) — Completed
• Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer — Completed
• Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence — Completed
• Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma — Stopped early
• EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck — Completed
• A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC) — Completed
• Trial of Dacarbazine With or Without Genasense in Advanced Melanoma — Completed
• MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma — Completed